Search

MSK leads the way in optimizing radiation treatment for breast cancer patients.

… Monday, October 31, 2016 Summary Radiation therapy after surgery helps cure most early-stage breast cancer patients. MSK has helped pioneer several radiation techniques that make the treatment more effective as well as safer for patients. The increased success of breast cancer treatment owes a great

Researchers at Memorial Sloan Kettering Cancer Center have identified, for the first time, an epigenetic mechanism promoting breast cancer. The team found that inhibition of the PI3K pathway leads to activation of ER-dependent transcription through the epigenetic regulator KMT2D. These findings provide a rationale for epigenetic therapy in patients with PIK3CA-mutant, ER-positive breast cancer. While epigenetic factors have been known to play an important role in various cancers such as leukemia and lymphoma, this is the first evidence found in breast cancer. This research co-led by José Baselga, MD, PhD, Physician-in-Chief and Chief Medical Officer, appears in the March 24, 2017 issue of Science. For more information on this work and to speak with the study authors, contact [email protected].

… Thursday, March 23, 2017 Bottom Line: Researchers from Memorial Sloan Kettering Cancer Center (MSK) have identified, for the first time, an epigenetic mechanism promoting breast cancer . The team found that inhibition of the PI3K pathway leads to activation of ER-dependent transcription through the epigenetic

This three-part series summarizes MSK’s recent advances in clinical research and novel treatment approaches for rare head and neck cancers.

… Friday, March 22, 2024 Part 1: Rare Salivary Cancers Memorial Sloan Kettering Cancer Center (MSK) has a comprehensive and integrated head and neck cancer program with dedicated resources and specialists who treat patients with rare salivary, thyroid, non-melanoma skin, and oral cavity cancers. Clinical

Findings Could Inform the Development of a Blood Test for Early Cancer Detection

… Saturday, June 3, 2017 Findings from an early study evaluating a sophisticated new genomic-sequencing approach that analyzes cell-free DNA (cfDNA) in the blood of people with advanced cancer will help inform development of a future assay that could potentially detect cancer in its earliest stages, according

Most children face pressures growing up — including from their parents and peers. Vik Gill wrestled with circumstances “that may sound more familiar to any child of first-generation immigrants.

… Friday, May 6, 2022 Most children face pressures growing up — including from their parents and peers. Vik Gill wrestled with circumstances “that may sound more familiar to any child of first-generation immigrants,” he says “I was raised in a pretty culturally Indian household,” says Vik, an analyst for

A multicenter team led by Memorial Sloan Kettering neurologist and researcher Ingo K. Mellinghoff has uncovered the relationship between two proteins that play a critical role in glioblastoma, the most common form of brain cancer.

… Thursday, July 1, 2010 Summary A multicenter team led by Memorial Sloan Kettering neurologist and researcher Ingo K. Mellinghoff has uncovered the relationship between two proteins that play a critical role in glioblastoma, the most common form of brain cancer. A multicenter team led by Memorial Sloan

Hartford Healthcare system in Connecticut has been selected as the first MSK Cancer Alliance member, established to enhance delivery of care, improve patient outcomes, and advance research.

… Tuesday, September 17, 2013 Summary Hartford Healthcare system in Connecticut has been selected as the first MSK Cancer Alliance member, established to enhance delivery of care, improve patient outcomes, and advance research. Memorial Sloan Kettering today launched a transformative initiative to improve

Scott Stuart, Chair of the Boards of Trustees and Governing Trustees at Memorial Sloan Kettering Cancer Center (MSK), has been recognized as a Notable Nonprofit Board Leader in the 2023 Crain’s New York Business special editorial feature.

… Tuesday, October 10, 2023 Scott Stuart, Chair of the Boards of Trustees and Governing Trustees at Memorial Sloan Kettering Cancer Center (MSK), has been recognized as a Notable Nonprofit Board Leader in the 2023 Crain’s New York Business special editorial feature. This list honors exceptional nonprofit

Dr. Mara Sherman's lab at the Sloan Kettering Institute is “all pancreas, all the time.” Learn how her research program is illuminating interactions between cancer cells and the dense weave of fibrous cells that surrounds and protects pancreatic tumors.

… Monday, June 24, 2024 While the overall five-year survival rate for pancreatic cancer is slowly improving, it remains discouragingly low — just 13%, according to the American Cancer Society . And the odds are even worse if the cancer is discovered after it has spread to other organs. Dr. Mara Sherman

IBM, WellPoint, Inc., and Memorial Sloan Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to patients through individualized, evidence-based medicine.

… Friday, February 8, 2013 IBM (NYSE: IBM ), WellPoint, Inc. (NYSE: WLP ), and Memorial Sloan Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to